Find uplifting stories about heroes, innovations, and solutions
696 results for "hemophilia b"
A 31-year-old London, Ontario man with hemophilia B just received Canada's first one-time gene therapy that could free him from a lifetime of treatments. Basel Abushawish is now dreaming of playing soccer for the first time in his life.
Basel Abushawish spent 31 years unable to play sports due to severe hemophilia B. After receiving Canada's first dose of breakthrough gene therapy, he's finally heading to the soccer field.
A groundbreaking hepatitis B treatment has achieved what was once thought impossible: completely clearing the virus from patients' bodies. One in five participants in recent trials are now virus-free, offering hope to 296 million people worldwide living with chronic hepatitis B.
A 26-year-old Louisiana man received the state's first gene therapy treatment for severe hemophilia A, potentially ending his need for lifelong infusions. The breakthrough treatment allows his body to produce the clotting protein it previously couldn't make.
A simple fingerstick test for hepatitis B is just as accurate as traditional lab testing, and delivers results in 60 minutes instead of days. This breakthrough could save lives by bringing testing to remote communities where 254 million people worldwide need better access to care.
A team of researchers across five countries just received $24 million to find a cure for hepatitis B, a virus that affects 300 million people worldwide. The five-year effort could finally bring hope to millions living with a disease that currently has no cure.
Researchers at UC San Francisco discovered how certain immune cells can cure chronic hepatitis B infections, solving a 15-year medical mystery. The breakthrough could help hundreds of millions of people worldwide beat a virus that kills over a million annually.
A breakthrough medication called bepirovirsen has functionally cured 20% of chronic hepatitis B patients within one year, marking the first major treatment advance in decades. The FDA is expected to decide on approval this October.
A team of scientists across five countries just received $24 million to pursue something 300 million people are waiting for: a cure for hepatitis B. The five-year project brings together researchers from Brazil, India, Senegal, Uganda, and the United States to turn laboratory discoveries into real treatments.
A groundbreaking treatment has achieved functional cures in one-fifth of chronic hepatitis B patients, offering hope for a disease that affects 296 million people worldwide. The weekly injection made the virus undetectable even after treatment stopped.
Australian researchers proved a simple fingerstick test detects hepatitis B as accurately as lab tests, delivering results in just one hour instead of weeks. The breakthrough could bring lifesaving treatment to 254 million people worldwide who lack access to testing.
A Wellesley couple whose son has severe hemophilia created a Bloody Mary competition that's become an annual fundraiser bringing together restaurants, families, and fun for a serious cause. Meanwhile, middle schoolers are collecting school supplies to help students in neighboring communities succeed.
For the first time, a new treatment called bepirovirsen has achieved functional cure in 1 in 5 hepatitis B patients, compared to nearly zero with current therapies. This breakthrough could free millions from lifelong daily medication.
A Wellesley couple whose young son has severe hemophilia A created a Bloody Mary competition that's now in its fourth year, raising funds and awareness while bringing the community together. Meanwhile, local middle schoolers are collecting surplus school supplies to help students in neighboring cities start the year ready to learn.
A groundbreaking study of 222,000 people found that higher levels of certain B vitamins could reduce stroke risk by up to 20 percent. The best part? You can get these protective nutrients from everyday foods like spinach, avocado, and whole grains.
A groundbreaking hepatitis B treatment is helping one in five patients stop therapy entirely while keeping the deadly liver virus undetectable. After decades of searching, researchers may have found the path to a functional cure for a disease that kills 1.1 million people yearly.
An experimental treatment by GSK achieved functional cures for nearly 20% of hepatitis B patients in major clinical trials, a massive leap from the 1-3% success rate of current medications. The breakthrough offers hope for millions living with a virus that kills a million people annually.
A groundbreaking hepatitis B treatment is letting patients stop therapy while keeping the deadly liver virus undetectable. The experimental drug achieved a "functional cure" in 20% of trial participants, a breakthrough decades in the making.
A new drug has functionally cured chronic hepatitis B in one in five patients, offering hope for the 254 million people living with the world's most common liver infection. The FDA is expected to decide on approval by October 2026.
An experimental medicine called bepirovirsen achieved functional cures in nearly 20% of chronic hepatitis B patients during clinical trials, a massive leap from current treatments that cure only 1% to 3%. For a disease killing 1 million people annually, this breakthrough could transform millions of lives.
Showing 20 of 696